Top Page
Nuwellis
(NASDAQ:NUWE)
Nuwellis (NUWE) vs. SPDR S&P 500 ETF (SPY)
Nuwellis Business Overview & Revenue Model
Nuwellis Earnings Call Summary
Nuwellis Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.74M | 8.86M | 8.54M | 7.92M | 7.44M |
| Gross Profit | 5.68M | 4.98M | 4.75M | 4.49M | 4.06M |
| EBITDA | -5.24M | -16.36M | -4.90M | -19.06M | -16.65M |
| Net Income | -10.62M | -20.21M | -14.53M | -19.58M | -15.84M |
Balance Sheet | |||||
| Total Assets | 9.86M | 9.77M | 24.67M | 30.42M | 20.01M |
| Cash, Cash Equivalents and Short-Term Investments | 5.09M | 3.80M | 18.31M | 24.20M | 14.44M |
| Total Debt | 545.00K | 760.00K | 984.00K | 1.18M | 339.00K |
| Total Liabilities | 3.33M | 6.56M | 12.32M | 4.47M | 3.69M |
| Stockholders Equity | 6.53M | 3.21M | 12.36M | 25.95M | 16.32M |
Cash Flow | |||||
| Free Cash Flow | -9.65M | -18.18M | -15.27M | -18.06M | -16.87M |
| Operating Cash Flow | -9.59M | -17.94M | -15.15M | -17.84M | -16.57M |
| Investing Cash Flow | -60.00K | 330.00K | 14.73M | -15.72M | -267.00K |
| Financing Cash Flow | 10.96M | 3.68M | 9.42M | 27.87M | 30.02M |
Nuwellis Technical Analysis
Nuwellis Risk Analysis
Nuwellis Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$17.74B | 5.78 | -7.44% | 3.51% | 11.55% | -28.15% | |
48 Neutral | $4.54M | ― | -496.27% | ― | -16.79% | -3.69% | |
45 Neutral | $1.20M | ― | -440.77% | ― | -1.21% | 93.72% | |
42 Neutral | $6.67M | ― | -155.20% | ― | 9.90% | 94.56% | |
41 Neutral | $2.25M | ― | -136.26% | ― | 9.57% | 10.03% | |
40 Underperform | $3.53M | ― | -145.09% | ― | ― | -10.29% | |
37 Underperform | $5.56M | ― | -120.16% | ― | -7.74% | 93.25% |
Nuwellis Corporate Events
Nuwellis, Inc. received a notice from Nasdaq on June 18, 2025, indicating that its stock price had fallen below $1.00 per share for 30 consecutive trading days, putting it at risk of delisting. However, by July 22, 2025, the company had resolved the issue, and Nasdaq confirmed that Nuwellis was back in compliance with listing standards, allowing its stock to continue trading on the Nasdaq Capital Market.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
On June 27, 2025, Nuwellis, Inc. appointed John L. Erb as the Chief Executive Officer and President, solidifying his leadership role after serving as interim CEO since February 2025. Mr. Erb, who has a long history with the company and extensive experience in the medical device sector, will continue to serve as Chairman of the Board. Additionally, the company announced a one-for-forty-two reverse stock split, approved by the board on June 19, 2025, to be effective on July 3, 2025, which aims to consolidate shares and adjust the stock’s market value, impacting shareholders and the company’s trading dynamics.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Nuwellis, Inc. has received a deficiency notice from Nasdaq due to its stock price falling below the minimum bid requirement of $1.00 for 30 consecutive trading days. The company, which previously conducted a reverse stock split in June 2024, is not eligible for the compliance period and faces potential delisting unless it requests a hearing. The board plans to implement another reverse stock split to regain compliance, but there is no assurance of success.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
On June 6, 2025, Nuwellis, Inc. filed a Certificate of Designation for Series F-1 Convertible Preferred Stock with the Delaware Secretary of State, authorizing the issuance of 100 shares. This new stock series is similar to the existing Series F Convertible Preferred Stock but includes a conversion limitation to prevent holders from exceeding 19.99% ownership of outstanding common stock. On June 9, 2025, Nuwellis entered into a Securities Exchange Agreement with CEO John L. Erb, exchanging 100 shares of the new Series F-1 Stock for the same number of existing Series F Stock, resulting in Mr. Erb owning 100% of the Series F-1 Stock.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
On May 20, 2025, Nuwellis held its annual stockholders meeting where key decisions were made. Two Class III directors were elected to the board for three-year terms, and a reverse stock split was approved to help maintain compliance with Nasdaq listing requirements. Additionally, Baker Tilly US, LLP was ratified as the independent public accounting firm for 2025, and provisions were made for potential adjournments to gather more proxy votes if needed.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
On May 9, 2025, Nuwellis, Inc. entered into a Supply & Quality Agreement with Kluge Design, LLC to manufacture and service the Aquadex product line. This agreement, which includes an upfront payment and volume-based payments, involves transferring certain employees to Kluge Design and has an initial term of three years, with automatic renewals. The agreement’s impact includes securing manufacturing capabilities for Nuwellis and ensuring the continuity of their product line, potentially strengthening their position in the medical device industry.
The most recent analyst rating on (NUWE) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.